Form 4: Kalaris Therapeutics Director David Hallal Acquires Stock Options

Director David Hallal acquired stock options for 18,000 shares of Kalaris Therapeutics, Inc. (KLRS) on April 10, 2025.

Summary

• On April 10, 2025, David Hallal, a director of Kalaris Therapeutics, Inc. (KLRS), was granted stock options to purchase 18,000 shares of common stock.
• The exercise price of the options is $7.31 per share.
• The options vest in equal monthly installments over three years, starting from March 18, 2025, and continuing through March 18, 2028, contingent upon continuous service.
• The options expire on April 9, 2035.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative. It's a neutral disclosure.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to increase shareholder value.

Key Dates

Keywords

stock options, Kalaris Therapeutics, KLRS, Form 4, director, David Hallal, beneficial ownership, equity securities